Filing Flows › Comparisons › LENZ vs XFOR
Lenz Therapeutics vs X4 Pharmaceuticals: LENZ and XFOR compared
Lenz Therapeutics is the larger company: $3.4M of revenue in its latest quarter (Q3 2026) against $2.8M for X4 Pharmaceuticals (Q3 2026). X4 Pharmaceuticals is growing faster (+75% against -73% a year earlier). X4 Pharmaceuticals is more profitable, with an operating margin of -714.0% against -972.8%.
Where the money goes: LENZ and XFOR
Lenz Therapeutics (LENZ) · Q3 2026
Lenz Therapeutics, Q3 2026: revenue $3.4M (-73% year over year), operating margin -972.8%, net loss $31.0M, operating cash flow −$22.3M. The chart follows the revenue to costs, profit and cash.
X4 Pharmaceuticals (XFOR) · Q3 2026
X4 Pharmaceuticals, Q3 2026: revenue $2.8M (+75% year over year), operating margin -714.0%, net loss $20.2M, operating cash flow −$20.2M. The chart follows the revenue to costs, profit and cash.
| Lenz Therapeutics (LENZ) | X4 Pharmaceuticals (XFOR) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $3.4M | $2.8M |
| Revenue growth, Y/Y | -73% | +75% |
| Operating margin | -972.8% | -714.0% |
| Net earnings | −$31.0M | −$20.2M |
| Net margin | -915.2% | -721.4% |
| Operating cash flow | −$22.3M | −$20.2M |
| Market value | — | $424M |
| P/E | — | 1.9× |
| Analysts’ mean target | — | $11.60 |
Where the revenue comes from
Lenz Therapeutics
- Product sales, net: $2.6M (77%)
- License revenue: $785K (23%)
Questions
Which is bigger, Lenz Therapeutics or X4 Pharmaceuticals?
Lenz Therapeutics is the larger company: $3.4M of revenue in its latest quarter (Q3 2026) against $2.8M for X4 Pharmaceuticals (Q3 2026).
Is Lenz Therapeutics or X4 Pharmaceuticals growing faster?
X4 Pharmaceuticals is growing faster (+75% against -73% a year earlier).
Which is more profitable, Lenz Therapeutics or X4 Pharmaceuticals?
X4 Pharmaceuticals is more profitable, with an operating margin of -714.0% against -972.8%.
More: Lenz Therapeutics earnings · how Lenz Therapeutics makes money · X4 Pharmaceuticals earnings · how X4 Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.